Letters to the Editor

COVID-19 Diagnostic Imaging: Caution Need Before the End of the Game.

From:

Luigi Vetrugno, MD, Daniele Orso, MD, Cristian Deana, MD, Flavio Bassi, MD, Tiziana Bove, MD

From the Department of Medicine, University of Udine, Italy, Anesthesia and Intensive Care Clinic, Via Colugna n° 50 33100 Udine, Italy (L.V., D.O., T.B.); University-Hospital of Udine, Department of Anesthesia and Intensive Care, P.le S. Maria della. Misericordia n° 15 33100 Udine, Italy (L.V., C.D., F.B., T.B.).

Dear Editor—We read the interesting letter of Khalili et al. about the role of lung ultrasound (LU) in diagnosing COVID-19 interstitial pneumonia during the recent SARS-CoV-2 global outbreak (1). We would like to present our different point of view. The Authors, after listing some of the benefits of LU, argue that it suffers from lower sensitivity than computed tomography (CT) and for this reason, it would not be useful in the diagnosis of COVID-19 pneumonia. However, Yang et al. compared LU and CT on 29 patients (for 540 lung regions) (2) and found that LU was more sensitive than CT in the diagnosis of regional alveolar–interstitial pattern, alveolar–interstitial syndrome, consolidations, and pleural effusion (60% vs. 38.5%; 93% vs. 69%; 39% vs. 3% and 74% vs. 16%, respectively). Khalili et al. correctly report that the most common imaging finding in COVID-19 pneumonia is widespread interstitial involvement. Therefore, we see no reason why LU cannot be used for the diagnosis of COVID-19 pneumonia, considering its comparable sensitivity, even superior to the CT scan. Furthermore, the recent study by Almeida Monteiro et al. confirmed the correlation between histological findings on lung biopsy and LU images (3). This report not only supports the correctness of the hypothesis (and his clinical and LU observations) of Volpicelli et al. (4) but also confirms the high sensitivity of LU in diagnosing COVID-19 pneumonia at different stages.

The second aspect that Khalili et al. seem not to have taken sufficiently into account is the prevalence of the disease during the COVID-19 epidemic peak. The medical chief of the Emergency Department of the main hospital in Bergamo reported seeing up to 60−80 suspected patients for COVID-19 in only a few hours (5). We do not know the size and resources of the hospital structure in which Khalili and colleagues work, but the execution of 30 CT scans per hour is simply inconceivable. In these circumstances the high sensitivity of LU (together with its safety, the possibility of performing it at the patient's bedside and of avoiding the transfer of a potentially infected patient around the hospital) is precisely the characteristic that makes LU the preferred tool for mass triage (6). Even though the incidence of COVID-19 seems to have decreased, and it is essential to be able to rule out lung involvement by COVID-19 in a vast portion of the asymptomatic population, LU appears to be the tool of choice. We have repeatedly stressed in our previous papers that LU does not seem to be adequately specific for COVID-19 pneumonia (7–9). But in this regard, a recent meta-analysis reports a very low specificity even for CT scan (10). Therefore, the specificity game between LU and CT scan is far from over. On one point, we agree with Khalili and colleagues: it would take adequately sized studies to establish the diagnostic accuracy of LU in terms of sensitivity and specificity. But we are confident that these studies will be soon available.

AUTHORS' CONTRIBUTIONS

DO and LV concept, design and drafting the manuscript. TB, CD, FB critical review the manuscript for important intellectual content. All authors read and approved the final manuscript.

CONFLICT OF INTEREST

None.

REFERENCES

1. Khalili N, Haseli S, Iranpour P. Lung Ultrasound in COVID-19 Pneumonia: Prospects and Limitations. Acad Radiol 2020; 20:S1076–S6332. doi:10.1016/j.acra.2020.04.032. 30244-0Epub ahead of print. PMID: 32444253; PMCID: PMC7196391.
2. Yang Y, Huang Y, Gao F, et al. Lung ultrasonography versus chest CT in COVID-19 pneumonia: a two-centered retrospective comparison study from China. Intensive Care Med 2020: 1–3. doi:10.1007/s00134-020-06096-1. Epub ahead of print. PMID: 32451581; PMCID: PMC7246293.
3. Almeida Monteiro RA, de Oliveira EP, Nascimento Saldiva PH, et al. Histological-ultrasonographical correlation of pulmonary involvement in severe COVID-19. Intensive Care Med 2020: 1–3. doi:10.1007/s00134-020-06125-z. Epub ahead of print. PMID: 32494927; PMCID: PMC7266913.
4. Volpicelli G, Lamorte A, Villén T. What's new in lung ultrasound during the COVID-19 pandemic. Intensive Care Med 2020: 1–4. doi:10.1007/s00134-020-06048-9. May 4Epub ahead of print. PMID: 32367169; PMCID: PMC7196717.
5. Italian Society for Emergency Medicine (SIMEU Available at: https://www.simeu.it/w/articoli/leggiArticolo/3977/leggi. [Accessed June, 10 2020]
6. Guarracino F, Vetrugno L, Forfori F. et al. Lung, heart, vascular and diaphragm ultrasound examination of COVID-19 patients: a comprehensive approach. J Cardiothorac Vasc Anesth. https://doi.org/10.1053/j.jcva.2020.06.013.
7. Vetrugno L, Bove T, Orso D, et al. Our Italian experience using lung ultrasound for identification, grading and serial follow-up of severity of lung involvement for management of patients with COVID-19. Echocardiography 2020; 37:625−627. doi:10.1111/echo.14664.
8. Vetrugno L, Bove T, Orso D, et al. Lung ultrasound and the COVID-19 "Pattern": Not all that glitter today is gold tomorrow published online ahead of print, 2020 May 8 J Ultrasound Med 2020. doi:10.1002/jum.15327.
9. Vetrugno L, Bove T, Orso D, et. al. B-lines in COVID-19: "Unspecificity" is not "Meaningless". Echocardiography 2020; doi:10.1111/echo.14768
10. Kim H, Hong H, Yoon SH. Diagnostic performance of CT and reverse transcriptase-polymerase chain reaction for coronavirus disease 2019: a meta-analysis. Radiology 2020. doi:10.1148/radiol.2020201343. Epub ahead of print. PMID: 32301646; PMCID: PMC7233409.